11/21
07:11 am
rnac
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit [Yahoo! Finance]
11/21
07:00 am
rnac
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Medium
Report
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
11/21
05:35 am
rnac
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics [Yahoo! Finance]
Low
Report
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics [Yahoo! Finance]
11/14
10:14 am
rnac
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 [Yahoo! Finance]
Medium
Report
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 [Yahoo! Finance]
11/8
02:32 pm
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target lowered by analysts at HC Wainwright from $45.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target lowered by analysts at HC Wainwright from $45.00 to $41.00. They now have a "buy" rating on the stock.
11/8
08:46 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
11/8
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
11/7
10:36 am
rnac
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
07:00 am
rnac
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
09:00 am
rnac
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Medium
Report
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
10/18
07:18 am
rnac
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock [Yahoo! Finance]
Medium
Report
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock [Yahoo! Finance]
10/16
08:31 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
10/15
07:00 am
rnac
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
Medium
Report
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
10/4
11:20 am
rnac
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? [Yahoo! Finance]
10/4
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
9/30
05:46 am
rnac
Gout (Chronic Refractory) Market Assessment 2024 Featuring 15 Companies and 20 Key Drugs - Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
Medium
Report
Gout (Chronic Refractory) Market Assessment 2024 Featuring 15 Companies and 20 Key Drugs - Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
9/13
08:02 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
9/9
07:00 am
rnac
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Low
Report
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
9/6
07:12 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grant [Yahoo! Finance]
High
Report
Cartesian Therapeutics Announces New Employment Inducement Grant [Yahoo! Finance]
9/6
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grant
High
Report
Cartesian Therapeutics Announces New Employment Inducement Grant
9/4
08:06 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
9/3
07:00 am
rnac
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Medium
Report
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
8/26
07:00 am
rnac
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Cartesian Therapeutics to Participate in Upcoming Investor Conferences